3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
17
Lymphoma, B-Cell
17
Lymphoma, Large B-Cell, Diffuse
16
Lymphoma, Non-Hodgkin
12
Recurrence
11
Burkitt Lymphoma
10
Multiple Myeloma
7
Lymphoma
7
Neoplasms
6
Leukemia, Myeloid, Acute
6
Lymphoma, Mantle-Cell
5
Leukemia
5
Pancreatic Neoplasms
4
Lymphoma, Follicular
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Hematologic Neoplasms
4
Carcinoma, Hepatocellular
4
Neoplasm, Residual
3
Nasopharyngeal Carcinoma
3
Leukemia, B-Cell
3
Glioma
3
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomach Neoplasms
2
Simpson-Golabi-Behmel syndrome
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Melanoma
2
Lymphoma, B-Cell, Marginal Zone
2
Interventions
Temozolomide
85
Radiotherapy
51
Bevacizumab
31
Irinotecan
19
Radiation
16
Carmustine
15
Magnetic Resonance Spectroscopy
14
Erlotinib Hydrochloride
14
O(6)-benzylguanine
11
Chemotherapy, Adjuvant
11
Carboplatin
9
sargramostim
8
Thalidomide
8
Imatinib Mesylate
8
Filgrastim
8
Surgical Procedures, Operative
6
Gene Expression Profiling
6
Drug Therapy
6
pembrolizumab
5
aldesleukin
5
Topotecan
5
Radiotherapy, Intensity-Modulated
5
Hydroxyurea
5
Gefitinib
5
Etoposide
5
Sorafenib
4
Immunohistochemistry
4
Dasatinib
4
Celecoxib
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gliosarcoma
×
Immunotherapy, Adoptive
×
Clear all
NCT02664363
2023-02-17
ExCeL
Duke University
Phase 1
Terminated
3 enrolled
8 charts